Frequency of Hypoglycemia and Its Significance in Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
BACKGROUND AND OBJECTIVES: This study set out to determine the incidence of hypoglycemia in patients with chronic kidney disease (CKD), with and without diabetes, and the association of hypoglycemia with mortality. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This was a retrospective cohort analysis of 243,222 patients who had 2,040,206 glucose measurements and were cared for at the Veterans Health Administration. CKD was defined as an estimated GFR of <60 ml/min per 1.73 m(2). Hypoglycemia was set at <70 mg/dl. Mortality was measured 1 day after glucose measurement. RESULTS: The incidence of hypoglycemia was higher in patients with CKD versus without CKD. Among patients with diabetes, the rate was 10.72 versus 5.33 per 100 patient-months and among patients without diabetes was 3.46 versus 2.23 per 100 patient-months, for CKD versus no CKD, respectively. The odds of 1-d mortality were increased at all levels of hypoglycemia but attenuated in CKD versus no CKD. Adjusted odds ratios for 1-d mortality that were associated with glucose values of <50, 50 to 59, and 60 to 69 mg/dl, respectively, versus glucose of >or=70 mg/dl were 6.09, 4.10, and 1.85 for inpatient records from patients with CKD; 9.95, 3.79, and 2.54 for inpatients records from patients without CKD; 6.84, 3.28, and 3.98 for outpatient records from patients with CKD; and 13.28, 7.36, and 4.34 for outpatient records from patients without CKD. CONCLUSIONS: CKD is a risk for hypoglycemia, with or without diabetes. The excessive mortality associated with hypoglycemia makes this complication a significant threat to patient safety in CKD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“CKD is a risk factor for non-diabetic hypoglycemia, as reflected in significantly higher hypoglycemia rates in patients with CKD compared to patients without CKD (3.46 vs. 2.23/100 patient-months, p < 0.0001) [29].”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 2×
“Both the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) and the Veterans Affairs Diabetes Trial (VADT) found that severe hypoglycemia was more common in an intensive glucose-lowering group than a control group, but the two treatment groups had similar m…”
BackgroundMethodInfluential(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Gerstein, H. C., Miller, M., & Byington, R. P. (2010) · Cited by 981
Frequency of Severe Hypoglycemia Requiring Emergency Treatment in Type 1 and Type 2 Diabetes
Leese, G. P., Wang, J., Broomhall, J., Kelly, P., Marsden, A., Morrison, W., Frier, B. M., Morris, A. D., & For the DARTS/MEMO Collaboration (2003) · Diabetes Care · doi:10.2337/diacare.26.4.1176 · Cited by 559 · cited 1×
“The selection of these cut points was derived from definitions of hypoglycemia used in previous studies (5, 17 ,18), but because none of them was used exclusively, we elected to incorporate all of them as measures of hypoglycemic severity.”
MethodMechanisms of abnormal cardiac repolarization during insulin-induced hypoglycemia
Robinson, R. T. C. E., Harris, N. D., Ireland, R. H., Lee, S., Newman, C., & Heller, S. R. (2003) · Diabetes · doi:10.2337/diabetes.52.6.1469 · Cited by 264 · cited 2×
“In addition, acute hypoglycemia can result in a surge in adrenergic activity, which can result in coronary ischemia, serious cardiac arrhythmias, and sudden death (7).”
BackgroundValidation of ICD-9-CM coding algorithm for improved identification of hypoglycemia visits
Ginde, A. A., Blanc, P. G., Lieberman, R. M., & Camargo, C. A. (2008) · BMC Endocrine Disorders · doi:10.1186/1472-6823-8-4 · Cited by 234
Snyder, R. W., & Berns, J. S. (2004) · Seminars in Dialysis · doi:10.1111/j.0894-0959.2004.17346.x · Cited by 215
Research works printed but not linked: 1
- [6]Berlin KS, Sass DA, Davies WH, Reupert S, Hains AA: Brief report: Parent perceptions of hypoglycemic symptoms in youth with diabetes. J Pediatr Psychol 30: 207–212, 2005 [DOI] [PubMed] [Google Scholar]
Cited by
Tuttle, K. R., Lakshmanan, M. C., Rayner, B., Busch, R. S., Zimmermann, A. G., Woodward, D. B., & Botros, F. T. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30104-9 · Cited by 648
Treatment of Diabetes in Older Adults: An Endocrine Society* Clinical Practice Guideline
LeRoith, D., Biessels, G. J., Braithwaite, S. S., Casanueva, F. F., Draznin, B., Halter, J. B., Hirsch, I. B., McDonnell, M. E., Molitch, M. E., Murad, M. H., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00198 · Cited by 568
“Notably, the decline in GFR reduces the clearance of insulin and many diabetes medications (404) and increases the risk of hypoglycemia (405, 406).”
Background11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes−2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s011 · Cited by 460
11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2019
American Diabetes Association (2019) · Diabetes Care · doi:10.2337/dc19-s011 · Cited by 398
“and a desire to mitigate high risks of CKD progression, CVD, and hypoglycemia (48,49).”
Background11. Microvascular Complications and Foot Care: Standards of Medical Care in Diabetes—2021
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s011 · Cited by 395
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s011 · Cited by 275
11. Chronic Kidney Disease and Risk Management: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s011 · Cited by 344
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s011 · Cited by 289
11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s011 · Cited by 318
Li, H., Tian, S., Chen, T., Cui, Z., Shi, N., Zhong, X., Qiu, K., Zhang, J., Zeng, T., Chen, L., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14099 · Cited by 272
Stevens, L. A., Viswanathan, G., & Weiner, D. E. (2010) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2010.03.010 · Cited by 270
“In the analyses of data from the Veterans Health Administration, patients with CKD were more likely to have a complication after surgery or episodes of hyperkalemia or hypoglycemia.(60,61) Education and involvement of primary care physicians, as well as specialists who take care of patients with CKD, such as cardiolog…”
Shurraw, S. (2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.537 · Cited by 269
“001 Normal 3233 (27) 2623 (30) 1062 (40) Subsidy 8203 (70) 5953 (67) 1447 (54) Index eGFR, mL/min/1.”
Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A., & Umpierrez, G. E. (2016) · Diabetes Care · doi:10.2337/dc14-2883 · Cited by 235
“Patients with chronic kidney disease and diabetes are at increased risk of hypoglycemia, particularly when using insulin (35).”
Background11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026
American Diabetes Association Professional Practice Committee for Diabetes*, Bajaj, M., McCoy, R. G., Balapattabi, K., Bannuru, R. R., Bellini, N. J., Bennett, A. K., Beverly, E. A., Briggs Early, K., ChallaSivaKanaka, S., et al. (2026) · Diabetes Care · doi:10.2337/dc26-s011 · Cited by 226
Glycemic Monitoring and Management in Advanced Chronic Kidney Disease
Galindo, R. J., Beck, R. W., Scioscia, M. F., Umpierrez, G. E., & Tuttle, K. R. (2020) · Endocrine Reviews · doi:10.1210/endrev/bnaa017 · Cited by 202
Papademetriou, V., Lovato, L., Doumas, M., Nylen, E., Mottl, A., Cohen, R. M., Applegate, W. B., Puntakee, Z., Yale, J. F., & Cushman, W. C. (2015) · Kidney International · doi:10.1038/ki.2014.296 · Cited by 210
Interactions between kidney disease and diabetes: dangerous liaisons
Pecoits-Filho, R., Abensur, H., Betônico, C. C. R., Machado, A. D., Parente, E. B., Queiroz, M., Salles, J. E. N., Titan, S., & Vencio, S. (2016) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-016-0159-z · Cited by 171
Hallan, S., Afkarian, M., Zelnick, L. R., Kestenbaum, B., Sharma, S., Saito, R., Darshi, M., Barding, G., Raftery, D., Ju, W., et al. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.10.027 · Cited by 158
“Thirdly, it is well known that CKD patients have reduced gluconeogenesis and increased risk of hypoglycemia (Moen et al. 2009).”
Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease
Lo, C., Toyama, T., Wang, Y., Lin, J., Hirakawa, Y., Jun, M., Cass, A., Hawley, C. M., Pilmore, H., Badve, S. V., et al. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011798.pub2 · Cited by 100
Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2019) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.07.017 · Cited by 156
Global trend of diabetes mortality attributed to vascular complications, 2000–2016
Ling, W., Huang, Y., Huang, Y.-M., Fan, R.-R., Sui, Y., & Zhao, H.-L. (2020) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01159-5 · Cited by 132
Renal Gluconeogenesis: An Underestimated Role of the Kidney in Systemic Glucose Metabolism
Legouis, D., Faivre, A., Cippà, P. E., & de Seigneux, S. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa302 · Cited by 151
The case for hypoglycaemia as a proarrhythmic event: basic and clinical evidence
Nordin, C. (2010) · Diabetologia · doi:10.1007/s00125-010-1752-6 · Cited by 157
Elliott, L., Fidler, C., Ditchfield, A., & Stissing, T. (2016) · Diabetes Therapy · doi:10.1007/s13300-016-0157-z · Cited by 135
“Diabetes patients with renal dysfunction are at an increased risk of hypoglycemia as many antidiabetic drugs are renally excreted [56].”
Backgroundthe Italian Diabetes Society and the Italian Society of Nephrology, Pugliese, G., Penno, G., Natali, A., Barutta, F., Di Paolo, S., Reboldi, G., Gesualdo, L., & De Nicola, L. (2020) · Journal of Nephrology · doi:10.1007/s40620-019-00650-x · Cited by 125
Marbury, T. C., Flint, A., Jacobsen, J. B., Derving Karsbøl, J., & Lasseter, K. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0528-2 · Cited by 130
“[14] showed that chronic renal disease is a significant risk factor for hypoglycemia in patients with or without diabetes.”
BackgroundBakris, G. L. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0713 · Cited by 145
“73 m(2), who are receiving treatment with oral antidiabetic drugs that are primarily eliminated by the kidneys.(3,69) Furthermore, CKD is associated with impaired kidney gluconeogenesis due to a decrease in tissue mass.”
BackgroundHypoglycemia in Patients with Diabetes and Renal Disease
Alsahli, M., & Gerich, J. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4050948 · Cited by 123
“23 per 100 patient-months, for CKD versus no CKD, respectively [7].”
BackgroundClinical management of the uraemic syndrome in chronic kidney disease
Vanholder, R., Fouque, D. P., Glorieux, G., Heine, G. H., Kanbay, M., Mallamaci, F., Massy, Z. A., Ortíz, A., Rossignol, P., Więcek, A., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)00033-4 · Cited by 135
Impaired Glucose and Insulin Homeostasis in Moderate-Severe CKD
de Boer, I. H., Zelnick, L., Afkarian, M., Ayers, E., Curtin, L., Himmelfarb, J., Ikizler, T. A., Kahn, S. E., Kestenbaum, B., & Utzschneider, K. (2016) · Journal of the American Society of Nephrology · doi:10.1681/asn.2015070756 · Cited by 106
Decreased Renal Gluconeogenesis Is a Hallmark of Chronic Kidney Disease
Verissimo, T., Faivre, A., Rinaldi, A., Lindenmeyer, M. T., Delitsikou, V., Veyrat‐Durebex, C., Heckenmeyer, C., Fernandez, M., Berchtold, L., Dalga, D., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021050680 · Cited by 114
“In addition, higher hypoglycemic risk has been associated with CKD in hospitalized patients, and may likely contribute to the enhanced mortality observed.(26,55) Whether the correlation of altered renal gluconeogenesis with structural lesion progression and renal function loss is merely an association, or whether modi…”
BackgroundMorales, J., & Schneider, D. (2014) · The American Journal of Medicine · doi:10.1016/j.amjmed.2014.07.004 · Cited by 128
Baldwin, D., Zander, J., Munoz, C., Raghu, P., DeLange-Hudec, S., Lee, H., Emanuele, M. A., Glossop, V., Smallwood, K., & Molitch, M. (2012) · Diabetes Care · doi:10.2337/dc12-0578 · Cited by 103
“Patients with diabetes and renal insufficiency present a greater challenge because of their increased risk for hypoglycemia, especially when the GFR is ,60 mL/min (21).”
BackgroundERK2 Mediates Metabolic Stress Response to Regulate Cell Fate
Shin, S., Buel, G. R., Wolgamott, L., Plas, D. R., Asara, J. M., Blenis, J., & Yoon, S.-O. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.06.020 · Cited by 103
“See also Figure diabetes, chronic kidney disease, and acute coronary syndromes are associated with higher death rate due to hypoglycemia (Cryer, 2012; Kosiborod et al., 2008; Moen et al., 2009).”
Williams, M. E., Lacson, E. K., Jr., Wang, W., Lazarus, J. M., & Hakim, R. M. (2010) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.09301209 · Cited by 105
Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease
Scheen, A. J. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.777428 · Cited by 91
“The excessive mortality associated with hypoglycemia makes this complication a significant threat to patient safety in CKD [56].”
BackgroundHypoglycemia, Chronic Kidney Disease, and Diabetes Mellitus
Alsahli, M., & Gerich, J. E. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.07.013 · Cited by 91
Diabetes Control and the Risks of ESRD and Mortality in Patients With CKD
Navaneethan, S. D., Schold, J. D., Jolly, S. E., Arrigain, S., Winkelmayer, W. C., & Nally, J. V. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.11.018 · Cited by 79
Solini, A., Penno, G., Bonora, E., Fondelli, C., Orsi, E., Trevisan, R., Vedovato, M., Cavalot, F., Cignarelli, M., Morano, S., et al. (2013) · Journal of the American Geriatrics Society · doi:10.1111/jgs.12381 · Cited by 74
Insulin Degludec: Pharmacokinetics in Patients with Renal Impairment
Kiss, I., Arold, G., Roepstorff, C., Bøttcher, S. G., Klim, S., & Haahr, H. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0113-2 · Cited by 75
“As exogenous insulin is primarily cleared via renal metabolism [1, 7–9], impaired renal function in patients with diabetes can result in decreased clearance of insulin”
BackgroundFrias, J. P., Lim, C. G., Ellison, J. M., & Montandon, C. M. (2010) · Diabetes Care · doi:10.2337/dc09-1822 · Cited by 73
“The most commonly implicated agent in our review was icodextrin-containing PD solution, which is used in treating end-stage renal disease, a condition with a heightened risk of hypoglycemia (2).”
BackgroundThe role of sulfonylureas in the treatment of type 2 diabetes
Tomlinson, B., Patil, N. G., Fok, M., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1999413 · Cited by 79
Kong, A. P. S., Yang, X., Luk, A., Ma, R. C. W., So, W. Y., Ozaki, R., Ting, R., Cheung, K., Ho, C. S., Chan, M. H. M., et al. (2014) · Diabetes Care · doi:10.2337/dc13-2507 · Cited by 74
“Aside from reduced glucose production (about one-fifth of the plasma glucose originated from renal gluconeogenesis), diabetic patients with CKD often have altered drug metabolism, autonomic neuropathy, and hypoglycemic unawareness, which culminate and place them at high risk of hypoglycemia (6).”
BackgroundCardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 78
Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016121372 · Cited by 72
Glycated hemoglobin and outcomes in patients with advanced diabetic chronic kidney disease
Kuo, I.-C., Lin, H. Y.-H., Niu, S.-W., Hwang, D.-Y., Lee, J.-J., Tsai, J.-C., Hung, C.-C., Hwang, S.-J., & Chen, H.-C. (2016) · Scientific Reports · doi:10.1038/srep20028 · Cited by 70
Tuttle, K. R., McKinney, T. D., Davidson, J. A., Anglin, G., Harper, K. D., & Botros, F. T. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12816 · Cited by 67
“In addition, patients with T2D and CKD are at a higher risk of hypoglycaemia compared with patients with T2D because of decreased gluconeogenesis by the kidney as well as decreased clearance of insulin and of some other diabetes medications.(4) Diabetes medications not cleared by the kidney and associated with a low r…”
BackgroundChronic Kidney Disease in the Elderly
Maw, T. T., & Fried, L. F. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.05.003 · Cited by 70
Rahhal, M.-N., Gharaibeh, N. E., Rahimi, L., & Ismail‐Beigi, F. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00286 · Cited by 68
The Role of Deprescribing in Older Adults with Chronic Kidney Disease
Triantafylidis, L. K., Hawley, C. E., Perry, L., & Paik, J. M. (2018) · Drugs & Aging · doi:10.1007/s40266-018-0593-8 · Cited by 70
Presence of Macroalbuminuria Predicts Severe Hypoglycemia in Patients With Type 2 Diabetes
Yun, J.-S., Ko, S.-H., Ko, S.-H., Song, K.-H., Ahn, Y.-B., Yoon, K.-H., Park, Y.-M., & Ko, S.-H. (2013) · Diabetes Care · doi:10.2337/dc12-1408 · Cited by 63
“In addition, the presence of chronic kidney disease (CKD) is an important risk factor for the development of hypoglycemia (12).”
BackgroundPeter, W. L. S., Wazny, L. D., & Patel, U. D. (2013) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328365b364 · Cited by 72
“For example, the incidence of hypoglycemia in CKD patients increases as glomerular filtration rate (GFR) declines because of decreased insulin clearance [4,5]; however, many healthcare providers do not monitor glucose status closely.”
BackgroundLi, J., Albajrami, O., Zhuo, M., Hawley, C. E., & Paik, J. M. (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02690320 · Cited by 61
Colagiuri, S., Matthews, D. R., Leiter, L. A., Chan, S. P., Sesti, G., & Marre, M. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.05.028 · Cited by 63
Bloomfield, H. E., Greer, N. L., Newman, D. R., MacDonald, R. H., Carlyle, M. H., FITZGERALD, P. J., Rutks, I. R., & Wilt, T. J. (2012) · PubMed · Cited by 89
Jensen, M. H., Kjølby, M., Hejlesen, O. K., Jakobsen, P. E., & Vestergaard, P. (2020) · Diabetes Care · doi:10.2337/dc19-2535 · Cited by 63
Self-reported Medication Adherence and Adverse Patient Safety Events in CKD
Hsu, K. L., Fink, J. C., Ginsberg, J. S., Yoffe, M., Zhan, M., Fink, W. J., Woods, C. M., & Diamantidis, C. J. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.03.026 · Cited by 59
Self-citationGalindo, R. J., Ali, M. K., Funni, S. A., Dodge, A. B., Kurani, S. S., Shah, N. D., Umpierrez, G. E., & McCoy, R. G. (2022) · Diabetes Care · doi:10.2337/dc21-1579 · Cited by 53
Adverse Safety Events in Chronic Kidney Disease: The Frequency of “Multiple Hits”
Chapin, E., Zhan, M., Hsu, V. D., Seliger, S. L., Walker, L. D., & Fink, J. C. (2009) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06210909 · Cited by 53
Self-citationWang, M.-Y., Zhang, Z., Zhao, S., Onodera, T., Sun, X.-N., Zhu, Q., Li, C., Li, N., Chen, S., Paredes, M., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.024 · Cited by 52
Zelniker, T. A., Raz, I., Mosenzon, O., Dwyer, J. P., Heerspink, H. H. J. L., Cahn, A., Goodrich, E. L., Im, K., Bhatt, D. L., Leiter, L. A., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.0660 · Cited by 52
Safety of liraglutide in type 2 diabetes and chronic kidney disease
Mann, J. F. E., Fonseca, V. A., Poulter, N. R., Raz, I., Idorn, T., Rasmussen, S., von Scholten, B. J., Mosenzon, O., & on behalf of the LEADER Trial Investigators (2020) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11881019 · Cited by 50
“This hypoglycemia benefit with liraglutide is of clinical interest because CKD is a significant risk factor for hypoglycemia development and the choice of alternative glucose-lowering drugs is restricted (36).”
BackgroundLess is More: Deprescribing Medications in Older Adults with Kidney Disease: A Review
Mohottige, D., Manley, H. J., & Hall, R. K. (2021) · Kidney360 · doi:10.34067/kid.0001942021 · Cited by 51
“Hypoglycemic events are independently a cause for substantial concern because of their severe sequalae, including dizziness, slurred speech, seizure, cognitive decline, functional decline, and confusion, or more acute events increasing the risk of cardiac ischemia or arrythmias (26,27).”
BackgroundRenal Tubular Handling of Glucose and Fructose in Health and Disease
Vallon, V., & Nakagawa, T. (2021) · Comprehensive physiology · doi:10.1002/cphy.c210030 · Cited by 54
Pathophysiology and Management of Hypoglycemiain End-Stage Renal Disease Patients: A Review
Gianchandani, R. Y., Neupane, S., Iyengar, J. J., & Heung, M. (2016) · Endocrine Practice · doi:10.4158/ep161471.ra · Cited by 54
Risk of hypoglycemia following hospital discharge in patients with diabetes and acute kidney injury
Hung, A. M., Siew, E. D., Wilson, O. D., Perkins, A. M., Greevy, R. A., Horner, J., Abdel-Kader, K., Parr, S. K., Roumie, C. L., Griffin, M. R., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1237 · Cited by 49
Metformin in Chronic Kidney Disease: Time for a Rethink
Heaf, J. G. (2014) · Peritoneal Dialysis International · doi:10.3747/pdi.2013.00344 · Cited by 53
“The risk of hypoglycemia doubles in the presence of CKD (12).”
BackgroundHypoglycemia in People with Type 2 Diabetes and CKD
Ahmad, I., Zelnick, L. R., Batacchi, Z., Robinson, N., Dighe, A., Manski-Nankervis, J.-A. E., Furler, J., O’Neal, D. N., Little, R., Trence, D., et al. (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.11650918 · Cited by 49
“CKD has also been associated with severe hypoglycemia in other studies (4,14), but the full burden of hypoglycemia among people with type 2 diabetes and CKD, including asymptomatic episodes, is not well defined.”
BackgroundInfluentialPierce, D. A., Russell, G., & Pirkle, J. L. (2015) · Annals of Pharmacotherapy · doi:10.1177/1060028015607559 · Cited by 48
“Patients with chronic kidney disease have demonstrated higher rates of both hyperkalemia and hypoglycemia compared to patients with normal renal function as well as a higher rate of mortality associated with hypoglycemia.(7,8) 607559 AOPXXX10.”
BackgroundHan, K., Yun, J., Park, Y., Ahn, Y., Cho, J., Cha, S., & Ko, S. (2018) · Clinical Epidemiology · doi:10.2147/clep.s169835 · Cited by 53
“CKD is also one of the well-known risk factors for SH due to its role in gluconeogenesis and drug clearance.(29) Using these meaningful clinical and laboratory variables, a risk prediction model for SH can be built from qualified clinical studies.”
Background[Consensus document on treatment of type 2 diabetes in patients with chronic kidney disease].
Gómez‐Huelgas, R., Martínez‐Castelao, A., Artola, S., Górriz, J. L., & Menéndez, E. (2014) · PubMed · Cited by 53
Renal Effects of DPP-4 Inhibitors: A Focus on Microalbuminuria
Haluzík, M., Frolík, J., & Rychlík, I. (2013) · International Journal of Endocrinology · doi:10.1155/2013/895102 · Cited by 51
Chu, Y.-W., Lin, H.-M., Wang, J.-J., Weng, S., Lin, C., & Chien, C.-C. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174601 · Cited by 47
Vanholder, R. C., Laecke, S. V., Glorieux, G., Verbeke, F., Castillo-Rodríguez, E., & Ortíz, A. (2018) · Toxins · doi:10.3390/toxins10060237 · Cited by 49
“Controlling hyperglycemia indeed is difficult in renal failure because of higher risk of hypoglycemia as compared to the diabetic population without CKD [268].”
BackgroundFrankel, A., Kazempour‐Ardebili, S., Bedi, R., Chowdhury, T. A., De, P., El‐Sherbini, N., Game, F. L., Gray, S. H., Hardy, D., James, J., et al. (2018) · Diabetic Medicine · doi:10.1111/dme.13676 · Cited by 48
Safety of medical therapy in patients with chronic kidney disease and end-stage renal disease
Weir, M. R., & Fink, J. C. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/01.mnh.0000444912.40418.45 · Cited by 44
“Our own observational data indicate that hypoglycemia in patients with CKD is a substantial clinical concern whether the patient is an inpatient or an outpatient (Table 2) [25].”
BackgroundSelf-citationLo, C., Jun, M., Badve, S. V., Pilmore, H., White, S. L., Hawley, C., Cass, A., Perkovic, V., & Zoungas, S. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009966.pub2 · Cited by 41
Sinclair, A. J., Dunning, T. L., Dhatariya, K., & an International Group of Experts (2019) · Diabetic Medicine · doi:10.1111/dme.14135 · Cited by 44
Luk, A. O., Li, X., Zhang, Y., Guo, X., Jia, W., Li, W., Weng, J., Yang, W., Chan, W. B., Ozaki, R., et al. (2016) · Diabetic Medicine · doi:10.1111/dme.13014 · Cited by 43
Lee, M., Huang, J., Chen, S., Chiou, H.-Y. C., & Wu, P.-Y. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124116 · Cited by 46
“Intensive control of HbA1C to achieve as low a level as possible is controversial in patients with CKD, as this can increase the risk of hypoglycemia due to the prolonged half-life of anti-diabetic drugs, reduced renal insulin clearance, degradation of insulin in peripheral tissues, glycogen storage, and renal glucone…”
BackgroundPenno, G., Russo, R., & Prato, S. D. (2013) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s28951 · Cited by 48
“73 m(2), insulin requirement is often reduced.(11) Therefore, hypoglycemia limits the ability to achieve and maintain glycemic control.”
Prescribing patterns of medicines in chronic kidney disease patients on maintenance hemodialysis
Chakraborty, S., Ghosh, S., Banerjea, A., De, R., Hazra, A., & Mandal, S. (2016) · Indian Journal of Pharmacology · doi:10.4103/0253-7613.190760 · Cited by 58
“72%.[19] Hypoglycemia in CKD is more likely to be a complication of insulin use rather than resulting from the renal disease per se.”
Xu, Y., Surapaneni, A., Alkas, J., Evans, M., Shin, J., Selvin, E., Chang, A. R., Grams, M. E., & Carrero, J. J. (2020) · Diabetes Care · doi:10.2337/dc20-1588 · Cited by 44
“Patients with CKD and type 2 diabetes have increased risk of hypoglycemia (5,6).”
BackgroundTseng, C., Lafrance, J., Lu, S., Soroka, O., Miller, D. R., Maney, M., & POGACH, L. M. (2015) · BMC Nephrology · doi:10.1186/s12882-015-0025-5 · Cited by 41
“The risk of morbidity and mortality increase in CKD patients with diabetes [20], highlighting the importance of assessing and managing risk factors associated with progression of CKD.”
BackgroundBalancing Hypoglycemia and Glycemic Control: A Public Health Approach for Insulin Safety
POGACH, L. M., & Aron, D. C. (2010) · JAMA · doi:10.1001/jama.2010.655 · Cited by 41
“98 for patients with chronic kidney disease.(6)”
Avoiding or coping with severe hypoglycemia in patients with type 2 diabetes
Yun, J., & Ko, S. (2015) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2015.30.1.6 · Cited by 43
“Diabetic patients with chronic kidney disease have a higher risk of hypoglycemia [66,69], due to the prolonged clearance of renal insulin or hypoglycemic agents and reduced renal gluconeogenesis (Table 4) [69].”
BackgroundNakamura, M., Satoh, N., Suzuki, M., Kume, H., Homma, Y., Seki, G., & Horita, S. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.04.005 · Cited by 40
Remote Usability Testing and Satisfaction with a Mobile Health Medication Inquiry System in CKD
Diamantidis, C. J., Ginsberg, J. S., Yoffe, M., Lucas, L., Prakash, D., Aggarwal, S., Fink, W. J., Becker, S., & Fink, J. C. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12591214 · Cited by 40
Self-citationHypoglycemia Incidence in Older Adults by Estimated GFR
Hodge, M. C., McArthur, E., Garg, A. X., Tangri, N., & Clemens, K. K. (2017) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2016.11.019 · Cited by 41
Diabetes Management in Older Adults With Chronic Kidney Disease
Clemens, K. K., O’Regan, N., & Rhee, J. J. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1128-3 · Cited by 42
Alawadi, F., Rashid, F., Bashier, A. M., Abdelgadir, E., Alsaeed, M., Abuelkheir, S., Khalifa, A. A., Sayyah, F., Bachet, F., Elsayed, M., et al. (2019) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2019.03.015 · Cited by 41
Baldwin, D., & Apel, J. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0339-7 · Cited by 41
Increased risk of stroke in patients with chronic kidney disease after recurrent hypoglycemia
Yu, T., Lin, C., Chang, S., Sung, F., & Kao, C. (2014) · Neurology · doi:10.1212/wnl.0000000000000711 · Cited by 39
“DISCUSSION In the present study, the incidence rate of hypoglycemia in patients with CKD was 4.5%, which is approximately twice the value noted in previous reports.3,7,15,18 Most previous studies were limited by the relatively small number of patients with CKD included in the study by the exclusion of cases with CKD.…”
BackgroundResultInfluentialThe management of severe hypoglycemia by the emergency system: The HYPOTHESIS study
Marchesini, G., Veronese, G., Forlani, G., Forlani, G., Ricciardi, L. M., & Fabbri, A. (2014) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2014.05.012 · Cited by 42
“9 atherotrombosis [24], as well as chronic kidney dis ease (in turn associated with cardiovascular mortality) [25].”
BackgroundHyperglycemia and Diabetes Mellitus Following Organ Transplantation
Galindo, R. J., & Wallia, A. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0707-1 · Cited by 39
The role of kidney in the inter-organ coordination of endogenous glucose production during fasting
Kaneko, K., Soty, M., Zitoun, C., Duchampt, A., Silva, M., Philippe, E., Gautier‐Stein, A., Rajas, F., & Mithieux, G. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.06.010 · Cited by 38
“Fasting hypoglycemia is one of the most important complications in CKD since it is associated with a higher mortality [12].”
BackgroundOnce-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
Trevisan, R., Conti, M., & Ciardullo, S. (2024) · Diabetologia · doi:10.1007/s00125-024-06158-9 · Cited by 37
“Older individuals and those with chronic kidney disease are at higher risk of hypoglycaemia and its sequelae [46, 47].”
BackgroundFu, H., Xie, W., Curtis, B. H., & Schuster, D. (2014) · Current Medical Research and Opinion · doi:10.1185/03007995.2014.922944 · Cited by 50
Tratamiento de la diabetes tipo 2 en el paciente con enfermedad renal crónica
Gómez‐Huelgas, R., Martínez‐Castelao, A., Artola, S., Górriz, J. L., & Torre, E. L. M. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.10.011 · Cited by 41
Cherney, D. Z. I., Hadjadj, S., Lawson, J., Mosenzon, O., Tuttle, K. R., Vrhnjak, B., Rasmussen, S., & Bain, S. C. (2022) · Kidney International Reports · doi:10.1016/j.ekir.2022.07.167 · Cited by 34
“73 m(2)), which is consistent with other published studies.(27) Although a higher proportion of patients discontinued treatment because of AEs with semaglutide versus comparators, discontinuation because ofAEs seemed to bemore likely in the subgroups with lower eGFR versus higher eGFR, and this tendency was more prono…”
Result
Metadata
- Authors
- Moen, M. F., Zhan, M., Hsu, V. D., Walker, L. D., Einhorn, L. M., Seliger, S. L., & Fink, J. C.
- Affiliations
- University of Maryland, Baltimore (US)
- Corresponding author
- Fink, Jeffrey C.
- Venue
- Clinical Journal of the American Society of Nephrology
- Published
- 2009-06
- Volume
- 4
- Issue
- 6
- Pages
- 1121-1127
- ISSN
- 1555-9041 (ISSN-L)
- PMC
- PMC2689888
- OpenAlex
- W2146702281
- Semantic Scholar
- 6dd714ce42c6670e1867d104de400f22b50a7e1c
- Cited by
- 423
- References
- 18
- Citations by year
- 2026: 14 · 2025: 18 · 2024: 21 · 2023: 22 · 2022: 28 · 2021: 32 · 2020: 47 · 2019: 31 · 2018: 37 · 2017: 26 · 2016: 27 · 2015: 36 · 2014: 26 · 2013: 23 · 2012: 19
- FWCI
- 8.50
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Journal of the American Society of Nephrology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (R21DK075675)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Nephrology › Dialysis and Renal Disease Management
- Keywords
- hypoglycemia, chronic kidney disease, diabetes mellitus, mortality, incidence, estimated glomerular filtration rate, veterans, patient safety, glucose monitoring
- MeSH terms
- Aged, Blood Glucose, Diabetic Nephropathies, Female, Glomerular Filtration Rate, Humans, Hypoglycemia, Male, Middle Aged, Retrospective Studies, Risk Factors, Comorbidity, Incidence, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.